Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$16.98 USD
+0.33 (1.98%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $17.00 +0.02 (0.12%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCKT 16.98 +0.33(1.98%)
Will RCKT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Other News for RCKT
RTW INVESTMENTS, LP Reduces Stake in Allurion Technologies Inc
Disney initiated, Cisco upgraded: Wall Street's top analyst calls
Rocket Pharmaceuticals initiated with bullish view at Scotiabank, here's why
Biotech Alert: Searches spiking for these stocks today
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves